Simultaneous Disruption of Interleukin (IL)-4 and IL-13 Defines Individual Roles in T Helper Cell Type 2-mediated Responses

By Grahame J. McKenzie,* Padraic G. Fallon,‡ Claire L. Emson,* Richard K. Grencis,§ and Andrew N. J. McKenzie*

From the *Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, U. Kingdom; the ‡Department of Pathology, University of Cambridge, Cambridge CB2 1QP, U. Kingdom; and the §School of Biological Sciences, University of Manchester, Manchester M13 9PT, U. Kingdom

Summary

Using a single vector targeting strategy, we have generated mice with a combined deficiency of interleukin (IL)-4 and IL-13 to clarify their roles in T helper type 2 (Th2) cell responses. Using immunological challenges normally characterized by a Th2-like response, we have compared the responses of the double-deficient mice with those generated by wild-type, IL-4–deficient, and IL-13–deficient mice. Using a pulmonary granuloma model, induced with Schistosoma mansoni eggs, we demonstrate that although eosinophil infiltration, immunoglobulin E, and IL-5 production are reduced in the IL-4–deficient mice and IL-13–deficient mice, they are abolished only in the combined absence of both cytokines. Furthermore, IL-4/13–deficient animals are severely impaired in their ability to expel the gastrointestinal nematode Nippostrongylus brasiliensis. Unexpectedly, N. brasiliensis–infected IL-4/13–deficient mice developed elevated IL-5 and eosinophilia, indicating that compensatory mechanisms exist for the expression of IL-5, although serum IgE remained undetectable. IL-4/13–deficient mice default to a Th1-like phenotype characterized by the expression of interferon γ and the production of IgG2a and IgG2b.

We conclude that IL-4 and IL-13 cooperate to initiate rapid Th2 cell–driven responses, and that although their functions overlap, they perform additive roles.

Key words: interleukin 4 • interleukin 13 • T helper type 2 cells • immunoglobulin E • eosinophilia

Although IL-4 is a key cytokine in the development of Th2 cell responses (1, 2), recent studies of IL-4R–mediated signaling pathways have implied the presence of alternative routes for Th2 cell induction (3–6). Indeed, we have recently identified that the closely related cytokine, IL-13, can also effect Th2 development (7), raising the question of how these two cytokines may compensate for one another during immune responses.

Both IL-4 and IL-13 are produced primarily by Th2-like cells (8–10) and mast cells (11), and in vitro assay systems have demonstrated that they share several biological functions. These include inducing human B cells to undergo Ig isotype switching to IgE (12) and regulating inflammatory responses by suppressing TNF-α and IL-1 expression from monocytes and macrophages (12–14). However, there are also specific functional differences between these molecules, most notable of which is the ability of IL-4 to induce T cell proliferation (15). Recent in vivo studies examining the clearance of the parasitic gastrointestinal nematode Nippostrongylus brasiliensis from the intestines of infected cytokine-deficient mice have also demonstrated divergent responses to IL-4 and IL-13. Although IL-4–deficient mice expelled N. brasiliensis worms with similar kinetics to wild-type mice, IL-13–deficient animals or mice treated with an inhibitor of IL-13 did not expel worms as efficiently (16, 17). Analysis of IL-4 and IL-13 receptor usage has explained certain aspects of the related responses. It is evident that both IL-4 and IL-13 can cross-compete for IL-4Rα, but that only IL-4 binds directly to this receptor chain (18). IL-13 binds to its own primary binding chain (IL-13Rα1), to which IL-4 does not bind, and recruits IL-4Rα into a receptor complex resulting in an increase in binding affinity and the initiation of signal transduction (19, 20). Further differential signaling pathways can be envisaged for the IL-4R, since IL-4 binding may recruit IL-13Rα1 or IL-2Rγc into its active receptor complex (21, 22). This complexity of receptor usage and the potential diversity of signaling pathways combine with the temporal and spatial expression
of the individual ligands to create a diversity of possible responses.

The genes encoding IL-4 and IL-13 are closely linked on human chromosome 5 and the syntenic region of mouse chromosome 11, and map to a cytokine gene cluster that also includes IL-5, IL-3, and GM-CSF (23, 24). To study the individual and combined contributions of IL-4 and IL-13 to immune responses, it would be advantageous to study mouse lines in which the expression of both cytokines had been disrupted; however, the close linkage of their genes precludes the generation of such lines by simple interbreeding of IL-4-deficient and IL-13-deficient mice. To circumvent these difficulties, we have used a single vector gene targeting strategy to simultaneously disrupt both the IL-4 and IL-13 genes, thereby allowing us to investigate the potential compensatory roles of these cytokines during Th2-dominated immune responses in vivo. Using a Th2-driven lung granuloma model, we demonstrate that IL-4 and IL-13 can partially compensate for each other and that granuloma formation is abolished only in the absence of both cytokines. Furthermore, we show that although IL-13 is primarily involved in the expulsion of *N. brasiliensis* the concomitant disruption of IL-4 further impairs parasite clearance. Interestingly, IL-4/13-deficient mice have demonstrated the existence of compensatory mechanisms that still enable the expression of IL-5 and subsequent eosinophilia after *N. brasiliensis* infection. We conclude that IL-4 and IL-13 act in concert to initiate rapid Th2-like responses, and that their combined disruption can either abolish such responses or significantly delay their onset, resulting in an inappropriate Th1 response.

## Materials and Methods

Targeted disruption of the *N. brasiliensis Il-13* and *Il-4* genes in Embryonic Stem Cells.

The single targeting vector consisted of 6 kb of the *Il-13* gene providing the 5' arm of homology and 4.0 kb of the *Il-4* gene comprising the 3' homology. The replacement vector was constructed to insert the neomycin resistance gene into an engineered Sall site in exon 3 of the *Il-13* gene. Stop codons in all three frames were inserted 5' of the selectable marker. The *Il-4* region was a HindIII fragment containing exon 3.5-d C57BL/6 blastocysts to generate chimeras. These mice were mated with C57BL/6 mice and transmitted the ES cell genotype to the germline. Mice homozygous for the disrupted allele through the germline. Mice homozygous for the disrupted allele were backcrossed 10 times onto C57BL/6. Wild-type C57BL/6 mice were included as controls in the schistosome egg experiments and showed similar phenotypes to the wild-type *129 × C57BL/6* (F1) controls. Therefore, for the sake of clarity only the wild-type *129 × C57BL/6* (F1) controls are presented.

Preparation of CD4+ T Cells.

Splenocytes were cultured on plastic tissue culture plates for 1 h at 37°C to remove macrophages. Nonaherent cells were incubated with biotinylated anti-I-Ak antibody (clone AF6-120.1; Becton Dickinson), biotinylated anti-CD8 antibody (clone 53-6.7; Becton Dickinson) and biotinylated anti-B220 antibody (clone R A3-6B2; Becton Dickinson), and streptavidin magnetic beads (MACS®; Miltenyi Biotec) followed by magnetic field separation to remove MHC class II, CD8, and B220-expressing cells. Cell purity was determined using FITC-labeled anti-CD4 and PE-labeled anti-CD8 antibodies and was generally 90-95% CD4+ cells. Purified cells were cultured on anti-CD3e antibody-coated plates (10 μg/ml of clone 2C11; Becton Dickinson) plus anti-CD28 antibody (1 μg/ml of clone 37.51; Becton Dickinson) in the presence of exogenous cytokines or anticytokine antibody as indicated. IL-2 (10 ng/ml; R&D Systems) was added to all cultures. Th2 cell differentiation was promoted in the presence of 10 ng/ml IL-4 (R&D Systems) and anti-IFN-γ antibody (10 μg/ml of clone XMG1.2; Becton Dickinson). Cells were cultured for 5 d, washed, and resuspended at 10^6 cells/ml for 24 h in the presence of anti-CD3. Supernatants were analyzed by cytokine ELISA performed as above.

Granuloma Formation.

Synchronous pulmonary granulomas were induced by intravenous injection of mice with *Schistosoma mansoni* eggs. *S. mansoni* eggs were isolated from the livers of infected mice as described (25). Mice were sensitized to schistosome eggs by intraperitoneal injection of 5,000 live eggs. 2 wk later, sensitized and naive mice, six mice per group, were injected intravenously with 5,000 eggs to induce synchronous pulmonary granulomas. 15 d after intravenous egg injection, mice were killed, serum was recovered, and the draining mediastinal lymph nodes were removed. The lungs were inflated with formal saline and processed for histology. The size (diameter in hematoxylin and eosin [H&E]-stained sections) and cell composition (percentage of eosinophils on Giemsa-stained sections) of the granuloma surrounding individual eggs were measured with an ocular micrometer using a double blind protocol by an investigator not involved in the study; >100 individual granulomas were analyzed per group. Cells were prepared from pooled mediastinal lymph nodes from each group and processed for cell culture as described (25). 3 × 10^5 cells/ml were cultured and restimulated with 10 μg/ml of soluble egg antigen. IL-4, IL-5, IL-10, and IFN-γ were assayed using ELISA. Egg antigen–specific IgE, IgG1, and IgG2a isotype responses were measured using ELISA as described (26). Statistical analysis was performed using analysis of variance (ANOVA) and Dunnett's test; P < 0.05 was considered significant.

*N. brasiliensis* Infection.

Individual mice were inoculated subcutaneously with 400 viable third-stage *N. brasiliensis* larvae.

OVA Immunization.

8-10-wk-old mice were immunized intraperitoneally with 100 μg of OVA adsorbed to aluminium hydroxide (OVA/alum) with subsequent boost injections with 100 μg of OVA/alum after 10 and 20 d. Serum samples were assayed for Ig isotypes.

ELISA Analysis.

Serum IgG was assayed using sandwich ELISA. 96-well plates were coated with anti-Ig isotype capture mAbs.
and bound Ig of diluted serum samples was detected using biotinylated anti-Ig isotype detection mAbs (Becton Dickinson). Concentrations were calculated using purified Ig isotypes as standards (Becton Dickinson). OVA-specific ELISAs were performed by coating 96-well plates with OVA at 2.5 μg/ml; bound Ig of diluted serum samples was detected using biotinylated anti-Ig isotype detection mAbs (Becton Dickinson). Cytokine ELISA also used the sandwich format, with capture and detection antibodies purchased from Becton Dickinson. ELISAs were performed according to Becton Dickinson’s ELISA protocol. The IL-13 ELISA was purchased from R& D Systems.

**Results**

Generation of Mice Double-deficient for IL-4 and IL-13. Since the IL-4 and IL-13 genes are closely linked on mouse chromosome 11 (~11 kb apart), it would be impractical to attempt to make IL-13-deficient mice with IL-4-deficient mice in order to generate a crossover event between these two genes. Therefore, we have used a single targeting construct to exploit their juxtaposition and simultaneously target both genes. The mouse IL-4 and IL-13 genes are transcribed in the same orientation, with the IL-13 gene lying upstream of the IL-4 gene (A.N.J. McKenzie, unpublished data). The targeting vector comprised a 5′ arm of homology derived from the IL-13 gene, and a 3′ arm of homology derived from the IL-4 gene positioned on either side of the neomycin resistance cassette (Fig. 1 A). The resulting homologous recombination event excises ~15 kb of intervening sequence. Genotyping of wild-type (IL-4+/+/IL-13+/+), heterozygous (IL-4+/−/IL-13+/−), and homozygous null (IL-4−/−/IL-13−/−) mice is shown in Fig. 1 B. The IL-4−/−/IL-13−/− mice were healthy and displayed no overt phenotypic abnormalities. Analysis of the IL-4−/−/IL-13−/− mice failed to detect IL-4 or IL-13 RNA transcripts from activated lymphocytes using reverse transcriptase PCR assays (data not shown), and ELISAs also failed to identify IL-4 or IL-13 protein in supernatants from spleen-derived CD4+ T cells cultured under Th2 cell differentiation conditions (Fig. 1 C). To determine the relative in vivo roles of IL-4 and IL-13, we have assessed the immune responses of the IL-4−/−/IL-13−/− animals in combination with IL-4-deficient mice (IL-4−/−) and IL-13-deficient mice (IL-13−/−), to a range of immunological challenges that normally provoke a Th2 phenotype.

Induction of Synchronous Pulmonary Granuloma Formation Using S. mansoni Eggs Is Abolished Only in the Combined Absence of IL-4 and IL-13. To determine the relative in vivo contribution of IL-4 and IL-13 in a Th2 cytokine-mediated inflammatory response, we used a model system in which synchronous pulmonary granuloma formation is induced around S. mansoni eggs (27). In this model, a cellular granulomatous response develops around parasite eggs that lodge in the lungs after their intravenous injection into mice. This inflammatory response is characterized by the high-level expression of Th2 cytokines (28).

We observed a profound inability of IL-4−/−/IL-13−/− mice to develop the Th2 cell-mediated inflammatory response normally generated during synchronous pulmonary granuloma formation in response to schistosome egg immunization (Fig. 2 A). This was in marked contrast to the response generated by wild-type mice in which large eosinophil-rich granulomas formed around eggs lodged in the lung alveoli (Fig. 2, A and B). Furthermore, this wild-type response was associated with expression of IL-4, IL-5, IL-10, and IL-13 by cells recovered from the draining mediastinal lymph nodes of the lung (Fig. 3 A) and the generation of increased titers of egg antigen–specific IgE and IgG1 (Fig. 3 B). By contrast, the IL-4−/−/IL-13−/− mice did not develop granulomas (Fig. 2 A), and eosinophil infiltration was virtually absent, although some monocyte infiltration was evident (Fig. 2 B). Correlating with this, schistosome egg-challenged IL-4−/−/IL-13−/− mice also expressed very low levels of IL-5 (Fig. 3 A), the primary cytokine in the induction of eosinophil differentiation (29). IL-10 production was also impaired, but there was a significant increase in the expression of IFN-γ (Fig. 3 A). Antigen-specific IgE was also not detected in the serum of IL-4−/−/IL-13−/− mice, and antigen-specific IgG1 was virtually absent (Fig. 3 B). We also assessed how IL-4-deficient mice and IL-13-deficient mice responded to schistosome egg challenge.
Although granuloma size and eosinophil infiltration were impaired in both single cytokine-deficient IL-4−/− and IL-13−/− mice, compared with wild-type (P < 0.001; Fig. 2, A–C), they continued to develop a Th2 response with the expression of IL-5 and the infiltration of eosinophils (Fig. 2 C and Fig. 3 A). Significantly, the granuloma response observed in both of the single cytokine gene-disruption mouse lines was substantially greater than that formed in the doubly targeted mice (Fig. 2, A and B). It is also noteworthy that both the IL-4−/− and IL-13−/− mice continued to produce egg antigen-specific IgE and IgG1, although the levels of these Ig isotypes were reduced relative to wild-type mice (Fig. 3 B).

Thus, the pulmonary granulomatous model demonstrates that mice deficient in either IL-4 or IL-13 are still capable of mounting a Th2-like response, albeit reduced compared with wild-type mice, but that simultaneous disruption of IL-4 and IL-13 results in abrogation of the granulomatous response. This demonstrates that IL-4 and IL-13 perform compensatory roles that are essential in combination for the successful development of a Th2 cell-driven inflammatory response, and that in their absence the response becomes dominated by the Th1 cell cytokine IFN-γ (Fig. 3 A).
mice with recombinant IL-4 results in the rapid expulsion of worms from these animals (data not shown). Thus, once again there is a dual effect of removing both IL-4 and IL-13, indicating that these cytokines act in combination to initiate a potent Th2 response.

IL-4/13-deficient mice fail to express IgE, but exhibit delayed IL-5 expression and eosinophilia in response to N. brasiliensis infection. The normal immune response to N. brasiliensis is characterized by Th2 cytokine expression, elevated levels of IgE expression, and eosinophilia (Fig. 5, A–C). Indeed, wild-type animals developed a profound eosinophilia by day 10 p.i. (Fig. 5 B), and total serum IgE had increased by ~100-fold by day 14 p.i. (Fig. 5 C). Unexpectedly, we found that IL-5 expression and eosinophilia were still induced in the IL-4/−/IL-13/− mice p.i. with N. brasiliensis, although their production was significantly delayed (Fig. 5, A and B). However, we failed to detect IgE expression in the serum of the IL-4/−/IL-13/− mice (Fig. 5 C), and levels of worm antigen-specific IgG1 were also undetectable (data not shown). Thus, we conclude that although IL-4 and IL-13 are required for the rapid initiation of Th2-like responses, alternative IL-4/IL-13-independent processes compensate for their loss and facilitate the expression of IL-5 and the coordinate development of eosinophilia.

A nitogen-specific antibody response is biased away from IgG1 and IgG2a and towards IgG2b in IL-4/13-deficient mice. Analysis of total serum IgG1 isotypes demonstrated that like the IL-4-deficient animals, mice lacking both IL-4 and IL-13 had 10–50-fold lower levels of serum IgG1 and undetectable levels of IgE, whereas other serum isotypes remained similar to wild-type (data not shown). However, due to the specific roles of Th2 cell cytokines in regulating humoral immune responses, we have also analyzed the antigen-specific Ig responses of wild-type, IL-4/−/IL-13/−, and IL-4/−/IL-13/− mice immunized with the protein antigen OVA complexed to alum. As shown in Fig. 6 A, the IL-4/−/IL-13/− animals are severely impaired in their ability to mount an IgG1 response, a deficiency also apparent in IL-4-deficient animals (Fig. 6 B).

Discussion

The generation and analysis of IL-4/13-deficient mice has enabled us to demonstrate conclusively that these cytokines cooperate in the development of Th2 cell-mediated immune responses. Due to the close proximity of the IL-4 and IL-13 genes, we used a single vector targeting strategy to disrupt the expression of both cytokine genes, thereby allowing us to dissect the potential compensatory roles played by these cytokines. To define their functional importance, we have used several model antigenic challenges that are normally characterized by Th2-like responses.

We have found that the Th2-like characteristics of synchronous pulmonary granuloma formation, including eosinophil infiltration and IgE production, are only abolished...
when both IL-4 and IL-13 are removed, whereas disruption of each individual cytokine resulted in only partial abrogation of the response. Thus, our data demonstrate for the first time that IL-13 also plays a significant role in granuloma formation and, since neither cytokine is fully able to compensate for the absence of the other, they illustrate a clear functional specificity for IL-4 and IL-13 in the development of the response. Even more significantly, the combined disruption of IL-4 and IL-13 results in the almost complete abolition of the Th2-driven granuloma response, demonstrating the additive roles of these two cytokines in the generation of Th2 responses. In the double-deficient mice, the virtual absence of eosinophil infiltration, antigen-specific IgE, and antigen-specific IgG1 is replaced by enhanced expression of IFN-γ and the upregulation of IgG2a (data not shown), both indicative of Th1-like responses. These data generated using the ligand-deficient mice also clarify any ambiguity raised by the results that have been generated using signal transducer and activator of transcription (Stat)6-deficient and IL-4Rα–deficient mice in which pulmonary granuloma responses were reported to be more enhanced expression of IFN-γ and the upregulation of IgG2a (data not shown), both indicative of Th1-like responses. These data generated using the ligand-deficient mice also clarify any ambiguity raised by the results that have been generated using signal transducer and activator of transcription (Stat)6-deficient and IL-4Rα–deficient mice in which pulmonary granuloma responses were reported to be more effectively reduced than in the IL-4–deficient mice (31–34).

Interestingly, although Th2 responses to N. brasiliensis infection are significantly delayed in the IL-4/13–deficient mice, our experiments have also identified alternative, IL-4– and IL-13–independent mechanisms for IL-5 production and eosinophilia in IL-4/13–deficient mice. Thus, even in the absence of IL-4 and IL-13, a response can develop Th2-like characteristics. The mechanism underlying the development of IL-5–producing cells is unclear. Such cells have been recognized in IL-4–deficient mice (2) and IL-4Rα–deficient mice (3) infected with N. brasiliensis, but normally only constitute a minor population when evaluated at 7 d p.i. This is also the case in the IL-4/13–deficient mice, where IL-5 expression at day 6 p.i. is very low. However, IL-5 levels in the double-deficient mice become highly elevated by day 10 p.i., indicating that, although significantly delayed, IL-5–producing cells can receive sufficient costimulation to expand in the absence of IL-4 and IL-13 signals. Since this phenomenon was not observed in the lung response to schistosome eggs, it may indicate a unique feature of the intestinal response to nematode infection.

To date, IgE responses by IL-4/13–deficient mice to a range of antigenic challenges have remained below the level of detection in ELISA assays, although IgG responses were detected in individual cytokine–deficient mice. These findings support previous studies which have identified IL-13 and IL-4 as alternative cytokines in the regulation of IgE expression (1, 2, 7, 36). Furthermore, in the combined absence of IL-4 and IL-13, the Ig response becomes more characteristic of a Th1 cell response, illustrating the additive roles played by these cytokines in the regulation of Ig expression. This was clearly demonstrated by assessing the antigen-specific Ig isotype response generated against protein antigen OVA immunization in the presence of the Th2-inducing adjuvant alum. Although the expression of IgG2a and IgG2b was only minimally enhanced after the individual disruption of IL-13, there was a significant increase when both IL-13 and IL-4 are cotargeted, indicating that at least in the regulation of Ig expression IL-4 appears able to compensate more effectively for the loss of IL-13 than IL-13 does after the disruption of IL-4.

**Figure 6.** Antigen-specific Ig response to OVA after immunization. (A) IL-13–deficient (○) and IL-4/13–deficient (△) mice (shown against preimmune [□] and wild-type [■] mice); (B) IL-4–deficient (■) mice (shown against preimmune [□] and C57BL/6 [●] mice). Cohorts of four animals were immunized intraperitoneally with 100 µg of OVA adsorbed to alum with subsequent boost injections of OVA/alum after 10 and 20 d. Serum samples were assayed by ELISA for Ig isotypes. Representative data from two repeat experiments are shown.
The development and analysis of mice with a combined deficiency for IL-4 and IL-13 expression have clearly demonstrated that IL-4 does not act in isolation in the development of Th2 cell responses. It is noteworthy that IL-4 and IL-13 share the α chain of the IL-4 receptor (37) and consequently signal through related pathways, including Stat6 (38). Our results now explain why IL-4R-α-deficient mice and Stat6-deficient mice display more severe phenotypic differences than were reported for the IL-4–deficient mice (3–5, 17). It is apparent that IL-4 and IL-13 act in conjunction to ensure the rapid onset of a Th2-like response and that in their combined absence the vestiges of the Th2 response are abolished or significantly delayed.

Th2 cell–driven responses, particularly IgE and eosinophilia, are instrumental in disease processes, including allergies, asthma, and helminth infections (29, 30, 39, 40). Indeed, recent studies have identified that IL-13 is also a major mediator in experimental models of allergic asthma (41, 42). Our findings have obvious implications for the development of therapeutic strategies for cytokine/anticytokine modulation of immune reactions. Thus, to control the initiation of Th2 cell responses and the abolition of IgE production, it appears that it will be necessary to inactivate both IL-4 and IL-13, and that even then default mechanisms may allow the development of eosinophilia. The IL-4/13-deficient mice will prove an important tool for dissecting the intimate interaction of these cytokines in numerous disease states.

The authors would like to thank Sarah Bell, Helen Jolin, David Matthews, and Michael Townsend for critical reading of this manuscript, and Emma Richardson for technical assistance.

Address correspondence and requests for materials to Andrew N.J. McKenzie, MRC Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 2QH, UK. Phone: 44-1223-402377; Fax: 44-1223-412178; E-mail: amn@mrc-lmb.cam.ac.uk

Received for publication 7 January 1999 and in revised form 18 March 1999.

References

1. Kuhn, R., K. Rajewsky, and W. Muller. 1991. Generation and analysis of interleukin-4–deficient mice. Science. 254:707–710.
2. Kopf, M., M. Le Gros, M. Bachmann, C. Lammers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 362:245–248.
3. Barner, M., M. Mohrs, F. Brombacher, and M. Kopf. 1998. Differences between IL-4Rα-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr. Biol. 8:669–672.
4. Shimoda, K., J. van Deursen, M. Sangster, S. Sarawar, R. Carson, R. Tripp, C. Chu, F. Quelle, T. N osaka, D. Vignali, et al. 1996. Lack of IL-4–induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature. 380:630–633.
5. Takeda, K., T. Tanaka, W. Shi, M. Matsumoto, M. Minami, S. Kashiwamura, N. Nakanishi, N. Yoshida, T. Kishimoto, and S. Akira. 1996. Essential role of Stat6 in IL-4 signalling. Nature. 380:627–630.
6. Kaplan, M., U. Schindler, S. Smiley, and M. Grusby. 1996. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity. 4:313–319.
7. McKenzie, G.J., C.L. Emson, S.E. Bell, S. Anderson, P. Falloon, G. Zurawski, R. Murray, and A.N.J. McKenzie. 1993. Impaired development of Th2 cells in IL-13-deficient mice. Immunity. 9:432–432.
8. Brown, K., S. Zurawski, T. Mosmann, and G. Zurawski. 1989. A family of small inducible proteins secreted by leukocytes are members of a new super-family that includes leukocyte and fibroblast-derived inflammatory agents, growth factors and indicators of various activation processes. J. Immunol. 142:679–687.
9. Mosmann, T., and R. Coffman. 1989. Th1 and Th2 cells different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 5:429–459.
10. McKenzie, A., J. Culpepper, R. de Waal Malefyt, F. Briere, J. Punnonen, G. Aversa, A. Sato, W. Dang, R. Cocks, S. Menon, et al. 1993. Interleukin-13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA. 90:3735–3739.
11. Burd, P.R., W.C. Thompson, E.E. Max, and F.C. Mills. 1995. Activated mast cells produce interleukin 13. J. Exp. Med. 181:1373–1380.
12. Punnonen, J., G. Aversa, B. Cocks, A. McKenzie, S. Menon, G. Zurawski, R. de Waal Malefyt, and J. de Vries. 1993. Interleukin-13 induces interleukin-4–independent IgG4 and IgE synthesis and CD23 expression by human B-cells. Proc. Natl. Acad. Sci. USA. 90:3730–3734.
13. Doherty, M.K., K. Kadzielnia, S. Menon, S. Andrade, and R. Coffman. 1993. Modulation of murine macrophage function by IL-13. J. Immunol. 151:7151–7160.
14. de Waal Malefyt, R., C. Figdor, R. Huijbens, S. Mohan, F. Briere, J. Punnonen, G. Aversa, A. Sato, W. Dang, G. Zurawski, R. de Waal Malefyt, and J. de Vries. 1993. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. J. Immunol. 151:6370–6381.
15. Yokota, T., T. Otuka, T. Mosmann, J. Bachereau, T. DeFrance, D. Blanchard, J. de Vries, F. Lee, and K. Arai. 1986. Isolation and characterization of a human interleukin cDNA clone, homologous to B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc. Natl. Acad. Sci. USA. 83:5894–5898.
16. McKenzie, G., A. Bancroft, R. Grencis, and A. McKenzie. 1998. A distinct role for interleukin-13 in Th2-cell-mediated immune responses. Curr. Biol. 8:339–342.
17. Urban, J., N. Oben-Trauth, D. Donaldson, K. Madden, S. Morris, M. Collins, and F. Finkelman. 1998. IL-13, IL-4R and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity. 8:255–264.
18. Zurawski, S., F. Vega, B. Huyghe, and G. Zurawski. 1993. R receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMB O (Eur. Mol. Biol. Org. J.). 12:3899–3905.

19. Hilton, D., J.-G. Zhang, D. Metcalfe, W. Alexander, N. Nicola, and T. Wilson. 1996. Cloning and characterization of a binding subunit of the interleukin 13 receptor that also is a component of the interleukin 4 receptor. Proc Natl Acad. Sci. USA. 93:497–501.

20. Aman, J., N. Tayebi, N. Obiri, R. Puri, W. Modi, and W. Leonard. 1995. cDNA cloning and characterization of the human IL-13 receptor α1 chain. J. Biol. Chem. 271:29265–29270.

21. Obiri, N., W. Debinski, W. Leonard, and R. Puri. 1995. R receptor for interleukin 13: interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, and 15. J. Biol. Chem. 270:8797–8804.

22. Miloux, B., P. Laurent, O. Bonnin, J. Luperk, D. Caput, N. Vita, and P. Ferrara. 1996. Cloning of the human IL-13Rα1 chain and reconstitution with the IL-4Rα chain of a functional IL-4/IL-13 receptor complex. FEBS Lett. 401:163–166.

23. McKenzie, A., X. Li, D. Largaespada, A. Sato, K. Atsushi, S. Zurawski, E. Doyle, A. Milatovich, U. Francke, N. Cope, and et al. 1993. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J. Immunol. 150:5436–5444.

24. Fraizer, K.A., Y. Ueda, Y. Zhu, V.R. Gifford, M.R. Garofalo, N. Mohandas, C.H. Martin, M.J. Palazzolo, J.F. Cheng, and E.M. Rubin. 1997. Computational and biological analysis of 680 kb of DNA sequence from the human 5q31 cytokine gene cluster. J. Biol. Chem. 270:19497–19503.

25. Fallon, P.G., P. Smith, and D.W. Dunne. 1998. Type 1 and type 2 cytokine-producing mouse CD4+ and CD8+ T cells in acute Schistosoma mansoni infection. Eur J. Immunol. 28(12):4061–4071.

26. Fallon, P.G., and D.W. Dunne. 1999. Tolerization of mice to Schistosoma mansoni egg antigens causes elevated type 1 and type 2 cytokine responses and increased mortality in acute infection. J. Immunol. 162:4122–4132.

27. Warren, K.S., and E.O. Domingo. 1970. Granuloma formation around Schistosoma mansoni, S. haematobium, and S. japonicum eggs. A Mer J. Trop. Med. Hyg. 19:291–304.

28. Wynn, T.A., I. Eltoum, A.W. Cheever, F.A. Lewis, W.C. Bach, and A. Sher. 1993. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151:1430–1440.

29. Sanderson, C.J. 1992. IL-5, eosinophils, and disease. Blood. 79:3101–3109.

30. Finkelman, F., T. Shea-Donohue, J. Goldhill, C. Sullivan, S. Morris, K. Madden, W. Gause, and J. Urban. 1997. Cytokine regulation of host defence against parasitic gastrointestinal nematodes lessons from studies with rodent models. A Rev. Immunol. 15:505–533.

31. Jankovic, D., M.C. Kullberg, P. Caspar, A.W. Cheever, N. Oben-Trauth, and A. Sher. 1998. Induction of egg pathology during Schistosoma mansoni infection requires IL-4 receptors, but not IL-4 expression. Second Woods Hole Immunopathology Meeting Summary Book. 2:52 (Abstr.).

32. Kaplan, M.H., J.R. Whitfield, D.L. Boros, and M.J. Grusby. 1998. Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response. J. Immunol. 160:1850–1856.

33. Pearce, E.J., A. Cheever, S. Leonard, Covalesky, R. Fernandez-Botran, G. Kohler, and M. Kopf. 1996. Schistosoma mansoni in IL-4-deficient mice. Int. Immunol. 8:435–444.

34. Metwali, A., D. Elliott, A.M. Blum, R. Lynch, N. Oben-Trauth, and J.V. Winstock. 1996. The granulomatous response in Schistosoma mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J. Immunol. 157:4546–4553.

35. Urban, J.F., C.R. Maliszewski, K.B. Madden, I.M. Katona, and F.D. Finkelman. 1995. Interleukin-4 treatment can cure established gastrointestinal nematode infections in immunocompetent and immunodeficient mice. J. Immunol. 154:4675–4684.

36. Emson, C.L., S.E. Bell, A. Jones, W. Wisden, and A.N.J. McKenzie. 1998. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J. Exp. Med. 189:398–400.

37. Zurawski, S., P. Chomarat, O. Djoussé, C. Bidaud, and G. Zurawski. 1995. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. Biol. Chem. 270:13869–13878.

38. Lin, J.-X., T.S. Migue, M. Tsang, M. Friedmann, J. Weatherbee, L. Zhou, A. Yamauchi, E. Bloom, J. Mitz, S. John, and W. Leonard. 1995. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-5. Immunity. 2:331–339.

39. Bousquet, J., P. Chanez, J.Y. Lacoste, G. Barneon, N. Ghanaiain, I. Ender, P. Venet, S. Ahlstedt, J. Simony-Lafontaine, and P. Godard. 1990. Eosinophilic inflammation in asthma. N Engl. J. Med. 323:1033–1039.

40. Marsh, D.G., J.D. Neely, D.R. Breazeale, B. Ghosh, L.R. Freidhoff, E. Ehrlich-Kautzky, C. Schou, G. Krishnaswamy, and T.H. Beaty. 1994. Linkage analysis of IL4 and other chromosome 5q31 markers and total serum immunoglobulin E concentrations. Science. 264:1152–1156.

41. Williams, R., M. J. Luyimbazi, X. Xu, B. Schofield, T.Y. N. Eben, C.L. Karp, and D.D. Donaldson. 1998. Interleukin-13: central mediator of allergic asthma. Science. 282:2258–2261.

42. Grunig, G., M. Wannock, A.W. Waks, R. Venkayya, F. Bromecker, D.M. Renick, D. Sheppard, M. Mohrs, D.D. Donaldson, R.M. Locksley, and D.B. Corry. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 282:2261–2263.